Symbols / OCS Stock $30.29 +0.23% Oculis Holding AG
OCS (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Ratings
Current target
$30.29
Low
$37.86
High
$64.27
Mean
$48.69
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-12 | main | Needham | Buy → Buy | $46 |
| 2026-05-12 | main | HC Wainwright & Co. | Buy → Buy | $47 |
| 2026-04-20 | reit | HC Wainwright & Co. | Buy → Buy | $44 |
| 2026-03-05 | main | Stifel | Buy → Buy | $50 |
| 2026-03-04 | main | HC Wainwright & Co. | Buy → Buy | $44 |
| 2026-03-04 | main | Needham | Buy → Buy | $40 |
| 2025-12-19 | main | Stifel | Buy → Buy | $40 |
| 2025-12-19 | init | JP Morgan | — → Overweight | $38 |
| 2025-12-03 | init | LifeSci Capital | — → Outperform | $55 |
| 2025-11-13 | main | B of A Securities | Buy → Buy | $29 |
| 2025-11-11 | main | Chardan Capital | Buy → Buy | $51 |
| 2025-11-11 | main | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-11-11 | reit | Needham | Buy → Buy | $36 |
| 2025-10-08 | main | Chardan Capital | Buy → Buy | $51 |
| 2025-10-07 | main | HC Wainwright & Co. | Buy → Buy | $36 |
| 2025-08-27 | init | Needham | — → Buy | $36 |
| 2025-08-22 | main | HC Wainwright & Co. | Buy → Buy | $33 |
| 2025-05-09 | main | Chardan Capital | Buy → Buy | $33 |
| 2025-04-17 | main | Chardan Capital | Buy → Buy | $28 |
| 2025-04-17 | main | HC Wainwright & Co. | Buy → Buy | $32 |
News
RSS: Latest OCS news- symbol__ Stock Quote Price and Forecast - CNN hu, 14 May 2026 03
- Board members at Oculis receive vested RSUs and new share awards - Stock Titan Fri, 15 May 2026 20
- Oculis Holding AG (OCS) reports Q1 loss, lags revenue estimates - MSN Fri, 15 May 2026 13
- Oculis Holding AG (NASDAQ:OCS) Q1 Earnings Miss Overshadowed by Key Pipeline Catalysts - ChartMill Mon, 11 May 2026 21
- A Look At Oculis Holding (OCS) Valuation After Key Phase 3 Clinical Milestones - simplywall.st hu, 14 May 2026 00
- Weighing Oculis Holding (NasdaqGM:OCS) Rich P/B Against DCF Upside After Strong Multi Year Share Gains - Yahoo Finance Mon, 11 May 2026 05
- H.C. Wainwright raises Oculis stock price target to $47 on trial progress - Investing.com Wed, 13 May 2026 12
- Oculis parks 9% of its stock as treasury shares after AGM vote - Stock Titan hu, 14 May 2026 20
- Oculis AGM Backs All Proposals, Adds Veteran Biotech CFO to Board and Expands Capital Flexibility - TipRanks hu, 14 May 2026 20
- Oculis Holding AG (OCS) Stock Analysis: A Promising Biotech with a 74.79% Potential Upside - DirectorsTalk Interviews Fri, 17 Apr 2026 07
- Is Oculis (OCS) Turning Regulatory Momentum In Ophthalmology Into A Durable Competitive Edge? - simplywall.st ue, 12 May 2026 16
- H.C. Wainwright raises Oculis stock price target to $47 on trial progress - Investing.com Nigeria Wed, 13 May 2026 13
- Oculis eye drop for diabetic vision loss nears June trial results - Stock Titan Mon, 11 May 2026 20
- Assessing Oculis Holding (OCS) Valuation As DIAMOND Phase 3 Trials Reach Key Completion Milestone - simplywall.st Sun, 26 Apr 2026 07
- Oculis (NASDAQ: OCS) clears AGM, adds new director and treasury share capacity - Stock Titan hu, 14 May 2026 20
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
81.67
+11.57%
|
73.20
+59.66%
|
45.85
+41.62%
|
32.38
|
| Research And Development |
|
57.09
+9.60%
|
52.08
+78.08%
|
29.25
+31.60%
|
22.22
|
| Selling General And Administration |
|
23.20
+22.60%
|
18.92
+28.50%
|
14.72
+118.36%
|
6.74
|
| General And Administrative Expense |
|
23.20
+22.60%
|
18.92
+28.50%
|
14.72
+118.36%
|
6.74
|
| Salaries And Wages |
|
15.00
+30.68%
|
11.48
+63.27%
|
7.03
+57.99%
|
4.45
|
| Other Gand A |
|
8.20
+10.14%
|
7.45
-3.25%
|
7.70
+235.44%
|
2.29
|
| Other Operating Expenses |
|
1.19
-42.56%
|
2.06
+13.54%
|
1.82
-45.55%
|
3.34
|
| Total Expenses |
|
81.67
+11.57%
|
73.20
+59.66%
|
45.85
+41.62%
|
32.38
|
| Operating Income |
|
-81.67
-11.57%
|
-73.20
-59.66%
|
-45.85
-41.62%
|
-32.38
|
| Total Operating Income As Reported |
|
-81.67
-11.57%
|
-73.20
+9.30%
|
-80.71
-149.30%
|
-32.38
|
| EBITDA |
|
-97.76
-15.16%
|
-84.89
+2.53%
|
-87.09
-173.00%
|
-31.90
|
| Normalized EBITDA |
|
-79.36
-12.35%
|
-70.63
-60.03%
|
-44.13
-38.13%
|
-31.95
|
| Reconciled Depreciation |
|
0.55
+34.48%
|
0.41
+41.46%
|
0.29
-4.01%
|
0.30
|
| EBIT |
|
-98.31
-15.25%
|
-85.30
+2.38%
|
-87.38
-171.36%
|
-32.20
|
| Total Unusual Items |
|
-18.41
-29.07%
|
-14.26
+66.80%
|
-42.96
-87769.39%
|
0.05
|
| Total Unusual Items Excluding Goodwill |
|
-18.41
-29.07%
|
-14.26
+66.80%
|
-42.96
-87769.39%
|
0.05
|
| Special Income Charges |
|
0.00
|
0.00
+100.00%
|
-34.86
|
0.00
|
| Restructuring And Mergern Acquisition |
|
0.00
|
0.00
-100.00%
|
34.86
|
0.00
|
| Net Income |
|
-98.96
-15.37%
|
-85.78
+3.41%
|
-88.80
-129.47%
|
-38.70
|
| Pretax Income |
|
-99.14
-15.37%
|
-85.94
+3.11%
|
-88.69
-129.52%
|
-38.64
|
| Net Non Operating Interest Income Expense |
|
0.94
-38.72%
|
1.53
+1241.23%
|
0.11
+101.80%
|
-6.32
|
| Interest Expense Non Operating |
|
0.83
+30.36%
|
0.64
-51.41%
|
1.31
-79.59%
|
6.44
|
| Net Interest Income |
|
0.94
-38.72%
|
1.53
+1241.23%
|
0.11
+101.80%
|
-6.32
|
| Interest Expense |
|
0.83
+30.36%
|
0.64
-51.41%
|
1.31
-79.59%
|
6.44
|
| Interest Income Non Operating |
|
1.77
-18.36%
|
2.17
+51.71%
|
1.43
+1034.13%
|
0.13
|
| Interest Income |
|
1.77
-18.36%
|
2.17
+51.71%
|
1.43
+1034.13%
|
0.13
|
| Other Income Expense |
|
-18.41
-29.07%
|
-14.26
+66.80%
|
-42.96
-87769.39%
|
0.05
|
| Gain On Sale Of Security |
|
-18.41
-29.07%
|
-14.26
-76.18%
|
-8.10
-16620.41%
|
0.05
|
| Tax Provision |
|
-0.19
-16.25%
|
-0.16
-249.53%
|
0.11
+94.55%
|
0.06
|
| Tax Rate For Calcs |
|
0.00
+0.75%
|
0.00
-97.81%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.03
-30.06%
|
-0.03
+99.27%
|
-3.65
-87769.39%
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-98.96
-15.37%
|
-85.78
+3.41%
|
-88.80
-129.47%
|
-38.70
|
| Net Income From Continuing Operation Net Minority Interest |
|
-98.96
-15.37%
|
-85.78
+3.41%
|
-88.80
-129.47%
|
-38.70
|
| Net Income From Continuing And Discontinued Operation |
|
-98.96
-15.37%
|
-85.78
+3.41%
|
-88.80
-129.47%
|
-38.70
|
| Net Income Continuous Operations |
|
-98.96
-15.37%
|
-85.78
+3.41%
|
-88.80
-129.47%
|
-38.70
|
| Normalized Income |
|
-80.58
-12.64%
|
-71.54
-44.54%
|
-49.50
-27.75%
|
-38.74
|
| Net Income Common Stockholders |
|
-98.96
-15.37%
|
-85.78
+3.41%
|
-88.80
-129.47%
|
-38.70
|
| Diluted EPS |
|
-1.89
+10.85%
|
-2.12
+28.62%
|
-2.97
+73.76%
|
-11.32
|
| Basic EPS |
|
-1.89
+10.85%
|
-2.12
+28.62%
|
-2.97
+73.76%
|
-11.32
|
| Basic Average Shares |
|
52.36
+29.58%
|
40.41
+35.14%
|
29.90
-8.66%
|
32.73
|
| Diluted Average Shares |
|
52.36
+29.58%
|
40.41
+35.14%
|
29.90
-8.66%
|
32.73
|
| Diluted NI Availto Com Stockholders |
|
-98.96
-15.37%
|
-85.78
+3.41%
|
-88.80
-129.47%
|
-38.70
|
| Depreciation Amortization Depletion Income Statement |
|
0.20
+49.64%
|
0.14
+117.46%
|
0.06
-12.50%
|
0.07
|
| Depreciation And Amortization In Income Statement |
|
0.20
+49.64%
|
0.14
+117.46%
|
0.06
-12.50%
|
0.07
|
| Depreciation Income Statement |
|
0.20
+49.64%
|
0.14
+117.46%
|
0.06
-12.50%
|
0.07
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets |
|
235.96
+96.06%
|
120.35
|
| Current Assets |
|
218.89
+108.67%
|
104.90
|
| Cash Cash Equivalents And Short Term Investments |
|
213.01
+115.90%
|
98.66
|
| Cash And Cash Equivalents |
|
81.33
+193.52%
|
27.71
|
| Cash Equivalents |
|
—
|
12.47
|
| Cash Financial |
|
—
|
15.23
|
| Other Short Term Investments |
|
131.68
+85.59%
|
70.95
|
| Receivables |
|
1.79
+18.49%
|
1.51
|
| Other Receivables |
|
0.99
+57.87%
|
0.63
|
| Taxes Receivable |
|
0.80
-9.49%
|
0.89
|
| Prepaid Assets |
|
4.08
-13.52%
|
4.72
|
| Total Non Current Assets |
|
17.07
+10.47%
|
15.46
|
| Net PPE |
|
3.00
+77.55%
|
1.69
|
| Gross PPE |
|
3.90
+56.03%
|
2.50
|
| Accumulated Depreciation |
|
-0.90
-11.12%
|
-0.81
|
| Properties |
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.55
+18.38%
|
0.47
|
| Other Properties |
|
3.16
+63.85%
|
1.93
|
| Leases |
|
0.18
+81.63%
|
0.10
|
| Goodwill And Other Intangible Assets |
|
13.29
+0.00%
|
13.29
|
| Other Intangible Assets |
|
13.29
+0.00%
|
13.29
|
| Investments And Advances |
|
—
|
—
|
| Non Current Deferred Assets |
|
—
|
—
|
| Non Current Deferred Taxes Assets |
|
—
|
—
|
| Other Non Current Assets |
|
0.79
+64.92%
|
0.48
|
| Total Liabilities Net Minority Interest |
|
39.89
-15.07%
|
46.97
|
| Current Liabilities |
|
36.75
-16.93%
|
44.23
|
| Payables And Accrued Expenses |
|
17.28
-15.20%
|
20.37
|
| Payables |
|
2.73
-53.82%
|
5.92
|
| Accounts Payable |
|
1.80
-69.34%
|
5.87
|
| Other Payable |
|
0.94
+1733.33%
|
0.05
|
| Current Accrued Expenses |
|
14.54
+0.62%
|
14.45
|
| Employee Benefits |
|
1.33
-28.61%
|
1.87
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
4.49
+21.51%
|
3.70
|
| Current Debt And Capital Lease Obligation |
|
0.50
+59.37%
|
0.32
|
| Current Capital Lease Obligation |
|
0.50
+59.37%
|
0.32
|
| Other Current Liabilities |
|
14.48
-27.07%
|
19.85
|
| Total Non Current Liabilities Net Minority Interest |
|
3.15
+15.03%
|
2.73
|
| Long Term Debt And Capital Lease Obligation |
|
1.81
+109.36%
|
0.86
|
| Long Term Debt |
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
1.81
+109.36%
|
0.86
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
1.33
-28.61%
|
1.87
|
| Tradeand Other Payables Non Current |
|
—
|
0.00
|
| Non Current Deferred Liabilities |
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
—
|
—
|
| Other Non Current Liabilities |
|
—
|
—
|
| Stockholders Equity |
|
196.07
+167.19%
|
73.38
|
| Common Stock Equity |
|
196.07
+167.19%
|
73.38
|
| Capital Stock |
|
0.59
+31.61%
|
0.45
|
| Common Stock |
|
0.59
+31.61%
|
0.45
|
| Share Issued |
|
58.69
+31.40%
|
44.66
|
| Ordinary Shares Number |
|
57.98
+32.80%
|
43.66
|
| Treasury Shares Number |
|
0.70
-29.63%
|
1.00
|
| Additional Paid In Capital |
|
551.73
+59.95%
|
344.95
|
| Retained Earnings |
|
-384.51
-34.65%
|
-285.56
|
| Gains Losses Not Affecting Retained Earnings |
|
-2.11
+15.58%
|
-2.50
|
| Treasury Stock |
|
0.01
-30.00%
|
0.01
|
| Total Equity Gross Minority Interest |
|
196.07
+167.19%
|
73.38
|
| Total Capitalization |
|
196.07
+167.19%
|
73.38
|
| Working Capital |
|
182.14
+200.26%
|
60.66
|
| Invested Capital |
|
196.07
+167.19%
|
73.38
|
| Total Debt |
|
2.31
+96.02%
|
1.18
|
| Net Debt |
|
—
|
—
|
| Capital Lease Obligations |
|
2.31
+96.02%
|
1.18
|
| Net Tangible Assets |
|
182.78
+204.17%
|
60.09
|
| Tangible Book Value |
|
182.78
+204.17%
|
60.09
|
| Duefrom Related Parties Current |
|
—
|
—
|
| Foreign Currency Translation Adjustments |
|
-0.48
-77.12%
|
-0.27
|
| Investmentin Financial Assets |
|
—
|
—
|
| Minimum Pension Liabilities |
|
-1.63
+26.82%
|
-2.23
|
| Other Equity Interest |
|
30.39
+89.19%
|
16.06
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-66.30
-35.54%
|
-48.92
+11.12%
|
-55.04
-119.50%
|
-25.07
|
| Cash Flow From Continuing Operating Activities |
|
-66.30
-35.54%
|
-48.92
+11.12%
|
-55.04
-119.50%
|
-25.07
|
| Net Income From Continuing Operations |
|
-99.14
-15.37%
|
-85.94
+3.11%
|
-88.69
-129.52%
|
-38.64
|
| Depreciation Amortization Depletion |
|
0.55
+34.48%
|
0.41
+41.46%
|
0.29
-4.01%
|
0.30
|
| Depreciation |
|
0.55
+34.48%
|
0.41
+41.46%
|
0.29
-4.01%
|
0.30
|
| Depreciation And Amortization |
|
0.55
+34.48%
|
0.41
+41.46%
|
0.29
-4.01%
|
0.30
|
| Other Non Cash Items |
|
3.98
+248.95%
|
-2.67
-106.75%
|
39.59
+511.88%
|
6.47
|
| Pension And Employee Benefit Expense |
|
0.10
+380.56%
|
-0.04
+78.95%
|
-0.17
-1800.00%
|
-0.01
|
| Stock Based Compensation |
|
16.04
+64.02%
|
9.78
+171.12%
|
3.61
+348.76%
|
0.80
|
| Operating Gains Losses |
|
12.39
-20.01%
|
15.49
+375.31%
|
3.26
+36322.22%
|
-0.01
|
| Gain Loss On Investment Securities |
|
12.29
-20.84%
|
15.53
+352.67%
|
3.43
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
—
|
-0.03
-105.15%
|
0.58
|
| Change In Working Capital |
|
-0.07
-100.52%
|
14.16
+209.01%
|
-12.99
-316.59%
|
6.00
|
| Change In Receivables |
|
-0.36
-247.37%
|
0.25
+586.11%
|
0.04
+123.68%
|
-0.15
|
| Change In Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Change In Payables And Accrued Expense |
|
-1.95
-121.57%
|
9.03
+221.31%
|
-7.44
-193.66%
|
7.95
|
| Change In Accrued Expense |
|
—
|
11.11
+196.23%
|
-11.55
-335.55%
|
4.90
|
| Change In Payable |
|
-1.95
-121.57%
|
9.03
+221.31%
|
-7.44
-344.56%
|
3.04
|
| Change In Account Payable |
|
-1.95
-120.70%
|
9.41
+220.28%
|
-7.82
-356.98%
|
3.04
|
| Change In Other Working Capital |
|
-0.11
-17.89%
|
-0.10
-227.59%
|
-0.03
|
—
|
| Change In Other Current Assets |
|
2.35
-52.84%
|
4.98
+189.65%
|
-5.56
-209.35%
|
-1.80
|
| Investing Cash Flow |
|
-60.93
-278.87%
|
-16.08
+69.64%
|
-52.97
-1393.04%
|
-3.55
|
| Cash Flow From Continuing Investing Activities |
|
-60.93
-278.87%
|
-16.08
+69.64%
|
-52.97
-1393.04%
|
-3.55
|
| Net PPE Purchase And Sale |
|
-0.30
-30.87%
|
-0.23
-379.17%
|
-0.05
+26.15%
|
-0.07
|
| Purchase Of PPE |
|
-0.30
-30.87%
|
-0.23
-379.17%
|
-0.05
+26.15%
|
-0.07
|
| Capital Expenditure |
|
-1.39
-503.48%
|
-0.23
-379.17%
|
-0.05
+98.65%
|
-3.55
|
| Net Investment Purchase And Sale |
|
-60.79
-250.82%
|
-17.33
+68.01%
|
-54.16
|
0.00
|
| Purchase Of Investment |
|
-60.79
-250.82%
|
-17.33
+68.01%
|
-54.16
|
0.00
|
| Net Intangibles Purchase And Sale |
|
-1.09
|
0.00
|
0.00
+100.00%
|
-3.48
|
| Purchase Of Intangibles |
|
-1.09
|
0.00
|
0.00
+100.00%
|
-3.48
|
| Financing Cash Flow |
|
186.92
+246.30%
|
53.98
-58.36%
|
129.63
+7462.78%
|
1.71
|
| Cash Flow From Continuing Financing Activities |
|
186.92
+246.30%
|
53.98
-58.36%
|
129.63
+7462.78%
|
1.71
|
| Net Issuance Payments Of Debt |
|
-0.37
-36.13%
|
-0.27
-73.42%
|
-0.16
+0.63%
|
-0.16
|
| Repayment Of Debt |
|
-0.37
-36.13%
|
-0.27
-73.42%
|
-0.16
+0.63%
|
-0.16
|
| Long Term Debt Payments |
|
-0.37
-36.13%
|
-0.27
-73.42%
|
-0.16
+0.63%
|
-0.16
|
| Net Long Term Debt Issuance |
|
-0.37
-36.13%
|
-0.27
-73.42%
|
-0.16
+0.63%
|
-0.16
|
| Net Common Stock Issuance |
|
178.86
+234.06%
|
53.54
-60.52%
|
135.62
|
0.00
|
| Cash Dividends Paid |
|
0.00
|
0.00
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
21.74
+494.50%
|
3.66
+102.60%
|
1.80
+1404.17%
|
0.12
|
| Net Other Financing Charges |
|
-13.22
-356.88%
|
-2.89
+61.87%
|
-7.59
-2640.07%
|
-0.28
|
| Changes In Cash |
|
59.68
+641.27%
|
-11.03
-151.01%
|
21.62
+180.33%
|
-26.91
|
| Effect Of Exchange Rate Changes |
|
-6.06
-1588.70%
|
0.41
+113.24%
|
-3.08
-835.65%
|
0.42
|
| Beginning Cash Position |
|
27.71
-27.71%
|
38.33
+93.71%
|
19.79
-57.24%
|
46.28
|
| End Cash Position |
|
81.33
+193.52%
|
27.71
-27.71%
|
38.33
+93.71%
|
19.79
|
| Free Cash Flow |
|
-67.69
-37.73%
|
-49.15
+10.78%
|
-55.09
-92.46%
|
-28.62
|
| Common Stock Issuance |
|
178.86
+234.06%
|
53.54
-60.52%
|
135.62
|
0.00
|
| Interest Paid CFF |
|
-0.09
-61.11%
|
-0.05
-17.39%
|
-0.05
|
—
|
| Interest Paid CFO |
|
—
|
-0.05
-17.39%
|
-0.05
+54.00%
|
-0.10
|
| Interest Received CFI |
|
1.24
-15.81%
|
1.47
+19.06%
|
1.24
|
—
|
| Interest Received CFO |
|
—
|
1.47
+19.06%
|
1.24
+882.54%
|
0.13
|
| Issuance Of Capital Stock |
|
178.86
+234.06%
|
53.54
-60.52%
|
135.62
+6580.54%
|
2.03
|
| Net Preferred Stock Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
2.03
|
| Preferred Stock Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
2.03
|
| Taxes Refund Paid |
|
-0.06
+63.82%
|
-0.15
-50.50%
|
-0.10
-405.00%
|
-0.02
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|